Phase 2Active, not recruiting

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia (ASCEND-QW)

A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Weekly Alirocumab in Adults With Hypercholesterolemia

Sponsor
Regeneron Pharmaceuticals (Industry)
Enrollment
438 enrolled
Conditions
Hypercholesterolemia
Interventions
Alirocumab
Ages
adults, older adults
Registry
NCT07477704

Full record on ClinicalTrials.gov

From the registry

This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels). The aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug once a week * How much study drug is in the blood at different times

Primary outcomes

  • Percent change in LDL-C

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered